Management of hepatitis C virus in the transplant patient.
Management of hepatitis C virus in the transplant patient.
复制标题
DOI：
10.1016/j.cld.2007.04.010
复制
发表时间：
2007-05-01
影响因子：
5.1
通讯作者：
Berenguer, Marina
中科院分区：
文献类型：
--
作者：
Berenguer, Marina
丙型肝炎病毒(丙型肝炎病毒)是慢性肝炎的主要原因，全球有1.7亿至1.9亿人感染。合并或不合并肝细胞癌的丙型肝炎病毒相关性肝硬变患者的首选治疗方法是肝移植。移植后病毒学复发是持续的，并导致绝大多数慢性肝炎。丙型肝炎病毒感染现在可以在相当大比例的肝移植接受者中治愈。这篇综述重点介绍了改善预后的可用策略，包括修改影响疾病进展的因素和抗病毒治疗的有效性。
Hepatitis C virus (HCV) is a leading cause of chronic hepatitis, with 170 to 190 million people infected worldwide. The treatment of choice for patients who have HCV-related cirrhosis with or without hepatocellular carcinoma is liver transplantation. Virologic recurrence is constant after transplantation and results in chronic hepatitis in the vast majority. HCV infection now can be cured in a substantial proportion of liver transplant recipients. This review highlights the available strategies to improve outcome, including modification of factors that affect disease progression and the efficacy of antiviral therapy.